1. Centers for Disease Control and Prevention. HIV Surveillance Report, 2016; vol. 28. Published November 2017. Accessed January 8, 2018.
  2. Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet. 2013;382(9903):1525-1533.
  3. Smit M, Brinkman K, Geerlings S, et al. Future challenges for clinical care of an ageing population infected with HIV: a modelling study. Lancet Infect Dis. 2015;15(7):810-818.
  4. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010;304(3):321-333.
  5. Günthard HF, Saag MS, Benson CA, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society-USA panel. JAMA. 2016;316(2):191-210.
  6. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Accessed on October 2, 2017.
  7. Hunt PW. HIV and aging: emerging research issues. Curr Opin HIV AIDS. 2014;9(4):302-308.
  8. Cysique LA, Waters EK, Brew BJ. Central nervous system antiretroviral efficacy in HIV infection: a qualitative and quantitative review and implications for future research. BMC Neurol. 2011;11:148.
  9. Wong MH, Roberson K, Nakasujja N, et al. Frequency of and risk factors for HIV dementia in an HIV clinic in sub-Saharan Africa. Neurology. 2007;68:350-355.
  10. American Academy of HIV Medicine, AIDS Community Research Initiative of America, and American Geriatrics Society. The HIV and aging consensus project: recommended treatment strategies for clinicians managing older patients with HIV. Accessed on October 2, 2017.
  11. Greene M, Justice AC, Lampiris HW, Valcour V. Management of human immunodeficiency virus infection in advanced age. JAMA. 2013;309(13):1397-1405.
  12. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state.” A practical method for crading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198.
  13. Gagliardi JP. Differentiating among depression, delirium, and dementia in elderly patients. Virtual Mentor. 2008;10(6):383-388.
  14. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Publishing, 2013.
  15. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69(18):1789-1799.
  16. Gandhi NS, Moxley RT, Creighton J, et al. Comparison of scales to evaluate the progression of HIV-associated neurocognitive disorder. HIV Ther. 2010;4(3):371-379.
  17. Heaton RK, Clifford DB, Franklin DRJ, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010;75(23):2087-2096.
  18. Simioni S, Cavassini M, Annoni JM, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS. 2010;24(9):1243-1250.
  19. Valcour VG. Evaluating cognitive impairment in the clinical setting: practical screening and assessment tools. Top Antivir Med. 2011;19(5):175-180.
  20. Saktor N. Changing clinical phenotypes of HIV-associated neurocognitive disorders. J Neurovirol. [Published online July 27, 2017]. J Neurovirol. doi: 10.1007/s13365-017-0556-6.
  21. Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55(RR-14):1-17.
  22. Sanders GD, Bayoumi AM, Holodniy M, Owens DK. Cost-effectiveness of HIV screening in patients older than 55 years of age. Ann Intern Med. 2008;148(12):889-903.
  23. Ellman TM, Sexton ME, Warshafsky D, Sobieszczyk ME, Morrison EA. A forgotten population: older adults with newly diagnosed HIV. AIDS Patient Care STDs. 2014;28(10):530-536.
  24. Lindau ST, Schumm LP, Laumann EO, Levinson W, O’Muircheartaigh CA, Waite LJ. A study of sexuality and health among older adults in the United States. New England Journal of Medicine. 2007;357(8):762-774.
  25. El-Sadr W, Gettler J. Unrecognized human immunodeficiency virus infection in the elderly. Arch Intern Med. 1995;155(2):184-186.
  26. Ramaswamy C, Ellman TM, Myers J, Madsen A, Sepkowitz K, Shepard C. Human immunodeficiency virus infection newly diagnosed at autopsy in New York City, 2008-2012. Open Forum Infect Dis. 2015;2(4):ofv146.
  27. Eisfeld C, Reichelt D, Evers S, Husstedt I. CSF penetration by antiretroviral drugs. CNS Drugs. 2013;27(1):31-55.
  28. Canestri A, Lescure FX, Jaureguiberry S, et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis. 2010;50(5):773-778.
  29. Joseph J, Cinque P, Colosi D, et al. Highlights of the Global HIV-1 CSF Escape Consortium Meeting, 9 June 2016, Bethesda, MD, USA.  J Virus Erad. 2016;2(4):243-250.
  30. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer’s disease. Alzheimers Dement. 2007;3(3):186-191.
  31. Elsawy B, Higgins KE. The geriatric assessment. Am Fam Physician. 2011;83(1):48-56.
  32. Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695-699.
  33. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the aged: The index of ADL: a standardized measure of biological and psychosocial function. JAMA. 1963;185:914-919.
  34. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9(3):179-186.
  35. Lowe B, Wahl I, Rose M, et al. A 4-item measure of depression and anxiety: validation and standardization of the Patient Health Questionnaire-4 (PHQ-4) in the general population. J Affect Disord. 2010;122(1-2):86-95.
  36. Podsiadlo D, Richardson S. The timed “Up & Go”: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991;39(2):142-148.
  37. Tinetti ME. Performance-oriented assessment of mobility problems in elderly patients. J Am Geriatr Soc. 1986;34(2):119-126.
  38. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146-M156.
  39. Vellas B, Balardy L, Gillette-Guyonnet S, et al. Looking for frailty in community-dwelling older persons: the Gerontopole Frailty Screening Tool (GFST). J Nutr Health Aging. 2013;17(7):629-631.
  40. O’Brien KK, Bayoumi AM, Strike C, Young NL, King K, Davis AM. How do existing HIV-specific instruments measure up? Evaluating the ability of instruments to describe disability experienced by adults living with HIV. Health Qual.Life Outcomes. 2010;8:88.
  41. EuroQol Research Foundation. EQ-5D-5L user guide: basic information on how to use the EQ-5D-5L instrument. Accessed on October 2, 2017.
  42. Desquilbet L, Jacobson LP, Fried LP, et al. HIV-1 infection is associated with an earlier occurrence of a phenotype related to frailty. J Gerontol A Biol Sci Med Sci. 2007;62(11):1279-1286.
  43. Morgan EE, Iudicello JE, Weber E, et al. Synergistic effects of HIV infection and older age on daily functioning. JAIDS. 2012;61(3):341-348.
  44. Erlandson KM, Allshouse AA, Jankowski CM, et al. Comparison of functional status instruments in HIV-infected adults on effective antiretroviral therapy. HIV Clin Trials. 2012;13(6):324-334.
  45. Justice AC. HIV and aging: time for a new paradigm. Curr HIV/AIDS Rep. 2010;7(2):69-76.
  46. Campbell JY, Durso SC, Brandt LE, Finucane TE, Abadir PM. The unknown profession: a geriatrician. J Am Geriatr Soc. 2013;61(3):447-449.
  47. John MD, Greene M, Hessol NA, et al. Geriatric assessments and association with VACS index among HIV-infected older adults in San Francisco. JAIDS. 2016;72(5):534-541.
  48. Singh HK, Del Carmen T, Freeman R, Glesby MJ, Siegler EL. From one syndrome to many: incorporating geriatric consultation into HIV care. Clin Infect Dis. 2017;65(3):501-506.
  49. Ruiz M, Cefalu C. Characteristics of frail patients in a geriatric-HIV program: the experience of an urban academic center at one year follow-up. J Int Assoc Physicians AIDS Care (Chic). 2011;10(3):138-143.
  50. Schifitto G, Navia BA, Yiannoutsos CT, et al. Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. AIDS. 2007;21(14):1877-1886.
  51. Simioni S, Cavassini M, Annoni JM, et al. Rivastigmine for HIV-associated neurocognitive disorders: a randomized crossover pilot study. Neurology. 2013;80(6):553-560.
  52. Erlandson KM, Allshouse AA, Duong S, Mawhinney S, Kohrt WM, Campbell TB. HIV, aging, and advance care planning: are we successfully planning for the future? J Palliat Med. 2012;15(10):1124-1129.
  53. Holtzman C, Armon C, Tedaldi E, et al. Polypharmacy and risk of antiretroviral drug interactions among the aging HIV-infected population. J Gen Intern Med. 2013;28(10):1302-1310.
  54. Edelman EJ, Gordon KS, Glover J, McNicholl IR, Fiellin DA, Justice AC. The next therapeutic challenge in HIV: polypharmacy. Drugs Aging. 2013;30(8):613-628.
  55. Duggan JM, Akpanudo B, Shukla V, Gutterson G, Eitniear L, Sahloff EG. Alternative antiretroviral therapy formulations for patients unable to swallow solid oral dosage forms. Am J Health-Syst Pharm. 2015;72:1555-1565.
  56. Jongbloed-de Hoon M, Colbers A, Velthoven-Graafland K, et al. Brief report: pharmacokinetics of crushed Elvitegravir combination tablet given with or without enteral nutrition. J Acquir Immune Defic Syndr. 2017;74(5):571-574.
  57. Taffé P, Rickenbach M, Hirschel B, et al; for the Swiss HIV Cohort Study. Impact of occasional short interruptions of HAART on the progression of HIV infection: results from a cohort study. AIDS. 2002;16(5):747-755.